Ocedurenone

Novo Nordisk Files $830M Fraud Lawsuit Against KBP Biosciences Over Failed Kidney Drug

3 months ago

• Novo Nordisk has initiated legal action against KBP Biosciences, seeking $830 million in damages over alleged misrepresentation of ocedurenone, a drug for hypertension and kidney disease. • The lawsuit claims KBP Biosciences failed to disclose crucial Phase II data showing ocedurenone's ineffectiveness and quality issues at test sites that produced false positive results. • A Singapore court has frozen the assets of KBP's founder Huang Zhenhua, ruling that Novo has an arguable case regarding conscious misrepresentation in the $1.3 billion drug acquisition deal.

Novel Therapies and Lifestyle Interventions Show Promise in Hypertension Management

8 months ago

• Recent trials highlight the potential of salt substitution and restriction in lowering blood pressure, particularly in elderly care facilities, showcasing significant cardiovascular benefits. • Emerging drug therapies, including aldosterone synthase inhibitors like baxdrostat and lorundrostat, demonstrate efficacy in treatment-resistant hypertension by targeting aldosterone production. • Bariatric surgery has shown sustained reductions in blood pressure over five years in obese patients with hypertension, suggesting a durable impact on cardiovascular health. • SGLT2 inhibitors, initially for diabetes, are recognized for their beneficial effects on blood pressure regulation, offering a dual-action approach for patients with both conditions.

Novo Nordisk Files $830M Fraud Lawsuit Against KBP Biosciences Over Failed Kidney Drug

Novel Therapies and Lifestyle Interventions Show Promise in Hypertension Management

Drug Development Updates